valbenazine
Selected indexed studies
- Valbenazine. (, 2006) [PMID:37748010]
- Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. (Lancet Neurol, 2023) [PMID:37210099]
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. (Am J Psychiatry, 2017) [PMID:28320223]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Comparative Analysis of Deutetrabenazine and Valbenazine as VMAT2 Inhibitors for Tardive Dyskinesia: A Systematic Review. (2024) pubmed
- Valbenazine and deutetrabenazine: Vesicular monoamine transporter 2 inhibitors for tardive dyskinesia. (2020) pubmed
- Valbenazine. (2006) pubmed
- Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial. (2023) pubmed
- KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. (2017) pubmed
- Valbenazine for the Treatment of Adults with Tardive Dyskinesia. (2021) pubmed
- Valbenazine for Tardive Dyskinesia. (2017) pubmed
- Valbenazine for the treatment of tardive dyskinesia. (2017) pubmed
- Valbenazine: First Global Approval. (2017) pubmed
- Valbenazine for the treatment of chorea associated with Huntington's disease. (2025) pubmed